Selection of the First <sup>99m</sup>Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Selection of the First <sup>99m</sup>Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Recently, radiolabelled antagonists targeting somatostatin receptors subtype 2 (SST2) in neuroendocrine neoplasms demonstrated certain superior properties over agonists. Within the ERA-PerMED project “TECANT” two <sup>99m</sup>Tc-Tetramine (N4)-derivatized SST2 antagonists (TECANT-1 and...

Full description

Bibliographic Details
Main Authors: Melpomeni Fani, Viktoria Weingaertner, Petra Kolenc Peitl, Rosalba Mansi, Raghuvir H. Gaonkar, Piotr Garnuszek, Renata Mikolajczak, Doroteja Novak, Urban Simoncic, Alicja Hubalewska-Dydejczyk, Christine Rangger, Piriya Kaeopookum, Clemens Decristoforo
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Pharmaceuticals
Subjects:
somatostatin receptor antagonist
SST2
Tc-99m
SPECT/CT
neuroendocrine tumours
Online Access:https://www.mdpi.com/1424-8247/14/1/19

Internet

https://www.mdpi.com/1424-8247/14/1/19

Similar Items